Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019
August 07, 2019 at 03:12 pm
Share
Chi Sheng Pharma & Biotech Co. Ltd. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced total revenue was TWD 258.504 million compared to TWD 237.313 million a year ago. Operating income was TWD 24.921 million compared to TWD 9.390 million a year ago. Net income was TWD 20.997 million compared to TWD 10.405 million a year ago. Basic earnings per share was TWD 0.37 compared to TWD 0.18 a year ago. For the half year, total revenue was TWD 499.680 million compared to TWD 482.114 million a year ago. Operating income was TWD 40.616 million compared to TWD 21.299 million a year ago. Net income was TWD 34.647 million compared to TWD 19.864 million a year ago. Basic earnings per share was TWD 0.61 compared to TWD 0.35 a year ago.
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
CHI SHENG PHARMA & BIOTECH CO., LTD 
